Technology | Hemodynamic Monitoring Systems | September 18, 2017

Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System

Small device features up to 32 bipolar intra-cardiac channels for EP procedures

Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System

September 18, 2017 — Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its QMAPP hemodynamic monitoring system.

The QMAPP amplifier is the size of a ream of A4 paper, features all available vital patient monitoring parameters and has up to 32 bipolar intra-cardiac channels for electrophysiology procedures. QMAPP is suitable for today’s hybrid rooms, but also for combined and dedicated cardiac catheterization labs, according to Fysicon. The system is fanless, which minimizes the risk of cross-contamination. The hardware design of QMAPP ensures a high level of usability. The unit is connected via one single cable to the floor base of the X-ray table and with a clamp mounted to the DIN-Rail. The acquired vitals and reporting entries can easily be exchanged with any electronic medical record (EMR) system using standard protocols like DICOM and HL7.

For more information: www.fysicon.com

Related Content

Shockwave Announces Collaboration With Abiomed on Physician Training
News | Cath Lab | December 14, 2018
Shockwave Medical announced a new investment and collaboration agreement with Abiomed Inc. As outlined by the agreement...
Sponsored Content | Videos | Cath Lab | October 24, 2018
Michael Flaherty, M.D., discusses a study published in Circulation Research which finds that use of hemodynamic suppo
Philips Showcases Integrated Solutions for Cardiovascular Care at TCT 2018
News | Cath Lab | September 20, 2018
At the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, Sept. 21–25 in San Diego, Philips is showcasing...
Sponsored Content | Videos | Cath Lab | September 19, 2018
William O’Neill, M.D., outlines his recent clinical publication of AMICS patients from the Impella Quality (IQ) datab
A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. DAIC staff photo by Dave Fornell

A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. (right) who is proctoring a fellow in treating CTOs.

Feature | Cath Lab | September 13, 2018 | Artur Kim, Kamran Zamanian
Coronary artery disease (CAD) is a multifaceted disease that demands various approaches in terms of diagnosis and tre
Videos | Cath Lab | August 13, 2018
Jeffrey Schussler, M.D., FACC, FSCAI, FSCCT, FACP, interventional cardiologist at Baylor Scott White Heart and Vascul
Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
Overlay Init